newsfilter
← Latest News
GlobeNewswire·

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications publication of